Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 8/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.55 |
| ▸ | GABRP | O00591 | 6/20 | 0.55 |
| ▸ | GABRD | O14764 | 6/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.55 |
| ▸ | GABRE | P78334 | 6/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.55 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918048 | 0.87 | TSHR (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7507673 | 0.84 | MIF (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27867975 | 0.81 | CHRNA7 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL55605 | 0.79 | CHRNA7 (0.48) | ALDH1A1CHRNA7HTR3AHTR3EHTR3B | |
| SCHEMBL29890580 | 0.77 | KMO (0.57) | ALDH1A1MAPTKDM4ESMN1; SMN2CHRNA7 | |
| SCHEMBL842797 | 0.77 | KMO (0.57) | ALDH1A1MAPTKDM4ESMN1; SMN2CHRNA7 | |
| SCHEMBL7504438 | 0.76 | CHRNA7 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30712292 | 0.76 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30712301 | 0.76 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2201127 | 0.76 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0911335-B1 | Method for producing furopyridine derivatives and intermediate compounds | KURARAY CO (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6342606-B2 | REACTING PYRIDINE ESTER DERIVATIVE WITH A REDUCING AGENT, AN ALKYLATING AGENT, AN ALKENYLATING AGENT, AN ARYLATING AGENT OR AN ARALKYLATING AGENT TO OBTAIN A PYRIDINE CARBONYL DERIVATIVE, REDUCING | KURARAY CO., LTD. (JP) | 2002-01-29 | — | — | US | disclosed |
| US-20010031871-A1 | Method for producing pyridine derivatives | KURARAY CO., LTD. (JP) | 2001-10-18 | — | — | US | disclosed |
| US-6265580-B1 | REACTING AMINE DERIVATIVE WITH CARBONYLATING AGENT AND NITRILE DERIVATIVE | KURARAY CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6111111-A | Intermediates for producing pyridine derivatives | KURARAY CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0911335-A2 | Method for producing furopyridine derivatives and intermediate compounds | KURARAY CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | GABRA1 3970/4885GABRG2 4187/4885GABRB3 3497/4885 |
| US-20010031871-A1 | Method for producing pyridine derivatives | CYP2E1, CBR1, CBR3 | GABRA1 2437/4885GABRG2 2662/4885GABRB3 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.